Plan B OTC Submission Fails On Lack Of Data In Teens
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs will continue to work with FDA toward approval of emergency contraceptive Plan B (levonorgestrel .75 mg) for OTC use, the company said in a May 6 statement
You may also be interested in...
FDA Topsiders Must Testify In Plan B Case – Judge
The Center for Reproductive Rights will be allowed to take depositions from certain FDA "senior decision-makers" in their suit against the agency over decisions related to emergency contraceptive Plan B
Emergency Contraception OTC Sale Backed By BMJ Study Authors
UK researchers advocate OTC sale of emergency contraception (EC) in the U.S., finding that nonprescription availability in Britain did not lead to an increase in unprotected sex
Plan B Highlighted By Senate Democrats In Crawford Confirmation Hearing
Senate Health Committee Democrats are asking to meet with FDA Commissioner nominee Lester Crawford to discuss the Rx-to-OTC switch of emergency contraceptive Plan B prior to voting on his confirmation